New drug therapies help people live longer, better lives. But in a world of increasing health costs, prescribing life-saving medications for our patients isn’t enough. Physicians, health plans and pharmaceutical manufacturers have to ensure that patien…
Companies as small as Nivien or as large as Pfizer find the chemical tools and run the experiments that prove or disprove medical hypotheses.
Experts are raising questions about FDA’s decision to expand the label of the diabetes drug Invokana to reduce the risk of cardiovascular events.
The fact is we want big pharma to work on these difficult challenges. No other entity can do this.
Given these plans, Chi-Med is open to U.S. partnerships for development of cancer therapies that incorporate fruquintinib.
Given these plans, Chi-Med is open to U.S. partnerships for development of cancer therapies that incorporate fruquintinib.
Given these plans, Chi-Med is open to U.S. partnerships for development of cancer therapies that incorporate fruquintinib.
Our slow progress against pancreatic cancer is representative of the war on cancer writ large. Focus in on pancreatic cancer, and you see that there has been progress for patients with some subtypes for the disease. There are real reasons for hope that…
If you were to ask the CEOs of Pfizer, Merck, Lilly, etc., they would be more than happy to drop the “user fees” and have Congress fully fund the FDA via other funding mechanisms.
The biopharmaceutical industry isn’t perfect. But let’s stop with the nonsense that the industry invents diseases. It’s not true.
